Advanced

Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms.

Gast, Gerrie-Cor M; Pop, Victor J M; Samsioe, Göran LU ; Grobbee, Diederick E; Nilsson, Peter M; Keyzer, Jules J; Wijnands-van Gent, Colette J M and van der Schouw, Yvonne T (2011) In Maturitas 70(4). p.373-378
Abstract
OBJECTIVES: We examined whether the association between hormone therapy (HT) use and coronary heart disease (CHD) risk differed between women with and without vasomotor symptoms (VMS). STUDY DESIGN: We used data from a Dutch (EPOS) and Swedish (WHILA) population-based sample of 8865 women, aged 46-64 years, and free of CHD, stroke, venous thrombosis/pulmonary embolism or cancer at baseline. Data on HT use, VMS and potential confounders were collected by questionnaires. MAIN OUTCOME MEASURES: CHD endpoints, obtained via registries. RESULTS: 252 CHD cases occurred during 10.3 years of follow-up. Neither for women with nor for women without flushing or (night) sweats ever HT use was associated with CHD risk, compared with never HT use. Among... (More)
OBJECTIVES: We examined whether the association between hormone therapy (HT) use and coronary heart disease (CHD) risk differed between women with and without vasomotor symptoms (VMS). STUDY DESIGN: We used data from a Dutch (EPOS) and Swedish (WHILA) population-based sample of 8865 women, aged 46-64 years, and free of CHD, stroke, venous thrombosis/pulmonary embolism or cancer at baseline. Data on HT use, VMS and potential confounders were collected by questionnaires. MAIN OUTCOME MEASURES: CHD endpoints, obtained via registries. RESULTS: 252 CHD cases occurred during 10.3 years of follow-up. Neither for women with nor for women without flushing or (night) sweats ever HT use was associated with CHD risk, compared with never HT use. Among women with intense VMS, ever HT use borderline significantly decreased CHD risk compared with never HT use (HR 0.48 [95% CI 0.20-1.03]). Among women without intense VMS, ever HT use was associated with a borderline significant increased CHD risk (HR 1.28 [95% CI 0.96-1.70]; P for interaction=0.02). However, after multivariate adjustment, as compared to never HT use, ever HT use was not associated with risk of CHD among women with or without intense VMS. CONCLUSIONS: In both groups of women with and without VMS, HT use does not seem to be associated with the risk of CHD. Hence, our findings do not support the view that HT use increases the CHD risk among women with an indication, i.e. VMS, but this needs to be confirmed in specifically designed studies. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Maturitas
volume
70
issue
4
pages
373 - 378
publisher
Elsevier
external identifiers
  • wos:000297882600012
  • pmid:21978631
  • scopus:80755133718
ISSN
1873-4111
DOI
10.1016/j.maturitas.2011.09.005
language
English
LU publication?
yes
id
167a2e0c-f9a7-4054-9a74-b414f422e3d7 (old id 2200760)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21978631?dopt=Abstract
date added to LUP
2011-11-02 08:19:14
date last changed
2017-11-19 03:08:11
@article{167a2e0c-f9a7-4054-9a74-b414f422e3d7,
  abstract     = {OBJECTIVES: We examined whether the association between hormone therapy (HT) use and coronary heart disease (CHD) risk differed between women with and without vasomotor symptoms (VMS). STUDY DESIGN: We used data from a Dutch (EPOS) and Swedish (WHILA) population-based sample of 8865 women, aged 46-64 years, and free of CHD, stroke, venous thrombosis/pulmonary embolism or cancer at baseline. Data on HT use, VMS and potential confounders were collected by questionnaires. MAIN OUTCOME MEASURES: CHD endpoints, obtained via registries. RESULTS: 252 CHD cases occurred during 10.3 years of follow-up. Neither for women with nor for women without flushing or (night) sweats ever HT use was associated with CHD risk, compared with never HT use. Among women with intense VMS, ever HT use borderline significantly decreased CHD risk compared with never HT use (HR 0.48 [95% CI 0.20-1.03]). Among women without intense VMS, ever HT use was associated with a borderline significant increased CHD risk (HR 1.28 [95% CI 0.96-1.70]; P for interaction=0.02). However, after multivariate adjustment, as compared to never HT use, ever HT use was not associated with risk of CHD among women with or without intense VMS. CONCLUSIONS: In both groups of women with and without VMS, HT use does not seem to be associated with the risk of CHD. Hence, our findings do not support the view that HT use increases the CHD risk among women with an indication, i.e. VMS, but this needs to be confirmed in specifically designed studies.},
  author       = {Gast, Gerrie-Cor M and Pop, Victor J M and Samsioe, Göran and Grobbee, Diederick E and Nilsson, Peter M and Keyzer, Jules J and Wijnands-van Gent, Colette J M and van der Schouw, Yvonne T},
  issn         = {1873-4111},
  language     = {eng},
  number       = {4},
  pages        = {373--378},
  publisher    = {Elsevier},
  series       = {Maturitas},
  title        = {Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms.},
  url          = {http://dx.doi.org/10.1016/j.maturitas.2011.09.005},
  volume       = {70},
  year         = {2011},
}